Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 13:24 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag PharmNovo får godkännande att inleda en fas 2a-studie med läkemedelskandidaten PN6047 i Spanien

STOCKHOLM, SVERIGE 9 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget PharmNovo fått godkänt av spanska myndigheter att inleda en klinisk fas 2a-studie med...
October 09, 2025 13:24 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain

STOCKHOLM, SWEDEN – October 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo has received approval from the Spanish regulatory...
October 03, 2025 02:30 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Dilafor beviljas patent i USA för tafoxiparin vid initiering av spontan förlossning

STOCKHOLM, 3 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Dilafor beviljats ett patent i USA som skyddar bolagets läkemedelskandidat tafoxiparin...
October 03, 2025 02:30 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor

STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in the US protecting its drug...
September 16, 2025 03:05 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag AnaCardio har slutfört rekryteringen i sin fas 2a-studie med läkemedelskandidaten AC01

STOCKHOLM, SVERIGE 16 september 2025 Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört patientrekryteringen i fas 2a-delen av den kliniska...
September 16, 2025 03:05 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its...
September 04, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data som visar på ihållande effekt av golexanolon i preklinisk Parkinsonmodell

STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger...
September 04, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate...
August 29, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Delårsrapport för januari – juni 2025

STOCKHOLM – den 29 augusti 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – juni 2025. Den fulla rapporten är tillgänglig på bolagets hemsida. ...
August 29, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Interim Report - January-June 2025

STOCKHOLM – 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website. “We have a...